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Abstract
Previous research has suggested autoimmune diseases are risk factors for developing venous 
thromboembolism (VTE). We assessed whether having diagnoses of selected autoimmune 
diseases associated with anti-phospholipid antibodies—autoimmune hemolytic anemia (AIHA), 
immune thrombocytopenic purpura (ITP), rheumatoid arthritis (RA), and systemic lupus 
erythematosus (SLE)—were associated with having a VTE diagnosis among US adult 
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hospitalizations. A cross-sectional study was conducted using the 2010 Nationwide Inpatient 
Sample of the Healthcare Cost and Utilization Project, Agency for Healthcare Research and 
Quality. VTE and autoimmune diseases were identified using International Classification of 
Diseases, Ninth Revision, Clinical Modification coded diagnoses information. The percentages of 
hospitalizations with a VTE diagnosis among all non-maternal adult hospitalizations without any 
of the four autoimmune diseases of interest and among those with AIHA, ITP, RA, and SLE 
diagnoses were 2.28, 4.46, 3.35, 2.65 and 2.77 %, respectively. The adjusted odds ratios (OR) for 
having a diagnosis of VTE among non-maternal adult hospitalizations with diagnoses of AIHA, 
ITP, RA, and SLE were 1.25 [95 % confidence interval (CI) 1.05–1.49], 1.20 (95 % CI 1.07–
1.34), 1.17 (95 % CI 1.13–1.21), and 1.23 (95 % CI 1.15–1.32), respectively, when compared to 
those without the corresponding conditions. The adjusted OR for a diagnosis of VTE associated 
with a diagnosis of any of the four autoimmune diseases was 1.20 (95 % CI 1.16–1.24). The 
presence of a diagnosis of AIHA, ITP, RA, and SLE was associated with an increased likelihood 
of having a VTE diagnosis among the group of all non-maternal adult hospitalizations.
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Introduction
Venous thromboembolism (VTE), which consists of deep vein thrombosis (DVT) and 
pulmonary embolism (PE), is an important health concern [1–3]. Research in the past 
several years has increasingly suggested that autoimmune diseases may be risk factors for 
VTE occurrence [4]. These have included studies that have reported a higher risk of VTE 
associated with autoimmune hemolytic anemia (AIHA), immune thrombocytopenic purpura 
(ITP), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), as well as several 
other autoimmune diseases [5–11]. For example, investigators in a case-control study among 
outpatients in a hospital in Italy found that SLE was one of the factors significantly 
associated with idiopathic DVT (OR 4.31, 95 % CI 3.14–5.48) [12]. A study among 30 
patients with AIHA in the US found that 8 (27 %) of these patients suffered a VTE event, 
either during the initial hemolytic crisis, relapse, or (as in one case) a surgical procedure [8].
Hospitalized patients with autoimmune disorders may particularly be at risk of VTE. 
Hospitalization itself is a strong risk factor for VTE [13, 14]; reasons for this likely include 
the VTE risks associated with immobility, surgery, and co-morbid conditions. Hospitalized 
patients with autoimmune diseases therefore may be at risk of hospital associated VTE 
because of the effects of both factors. Increased epidemiologic understanding of the 
association between autoimmune diseases and VTE can help to better assess the risk for 
VTE among hospitalized patients and develop and implement appropriate prevention 
strategies. This study assesses the association between VTE, whether occurring during or 
before hospitalization, and selected autoimmune diseases in a large sample of 
hospitalizations in the US; we focus on the autoimmune diseases, SLE, RA, ITP, and AIHA. 
Our objectives were to estimate the percent of hospitalizations with recorded diagnoses of 
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AIHA, ITP, RA, SLE, or any combination of these diseases that also had recorded diagnoses 
of VTE and to assess if those with these autoimmune diseases had an increased likelihood of 
having a VTE diagnosis compared to hospitalizations without these diagnoses.
Methods
This study used data from the National Inpatient Sample (NIS), Healthcare Cost and 
Utilization Project (HCUP), Agency for Healthcare Research and Quality. In 2010, the 
Nationwide Inpatient Sample database included information on inpatient stays from 
approximately 1,000 hospitals (~20 % of community hospitals in the US) in 45 states 
(comprising 96 % of the US population). Information collected on each discharge included 
dates of hospitalization, patient’s sex, age, and race/ethnicity as well as International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coded 
information on diagnoses and performed procedures. The dataset also includes information 
on whether the patient underwent major surgery during the hospitalization (derived from 
ICD-9-CM coded information available for the hospitalization). More detailed information 
about the Nationwide Inpatient Sample data is available at the following website: http://
www.hcup-us.ahrq.gov/nisoverview.jsp.
A cross-sectional approach was used with hospitalization as the unit of analysis. All 
hospitalizations for non-maternal causes (did not have a maternal diagnosis or procedure) 
where the patient’s age was ≥19 years were included in this study. Hospitalizations with 
recorded diagnoses of VTE were defined as those with ICD-9-CM codes indicating 
diagnoses of DVT, PE, or both, as any of the up to 25 listed diagnoses. The diagnosis of the 
four selected autoimmune diseases and the presence of selected medical conditions (cancer, 
congestive heart failure, stroke, long bone fracture, infection) that have been reported to be 
risk factors [3, 15] for VTE as well as venous catheterization [3] (also a reported risk factor 
for VTE) during hospitalization were also identified using ICD-9-CM coded diagnoses and 
procedure information. The ICD-9-CM codes used in this study to identify various 
diagnoses and venous catheterization are presented in Appendix.
Analysis
The association of a diagnosis of VTE with the recorded diagnosis of each or any of the 4 
selected autoimmune diseases was assessed using logistic regression analysis. Unadjusted 
odds ratios (OR) for recorded diagnoses of VTE associated with hospitalizations with 
recorded diagnoses of AIHA, ITP, RA, or SLE (when compared to hospitalizations without 
a diagnosis of the respective autoimmune disease) were derived using a separate model for 
each disease where only the disease was included as the explanatory variable; adjusted OR 
were derived using a model where the explanatory variables were all four autoimmune 
diseases of interest, patient sex, age, race/ethnicity, length of hospital stay, selected medical 
conditions, venous catheterization, and major surgery. Similarly, in separate models, 
unadjusted and adjusted OR were also derived for hospitalizations with a recorded diagnosis 
of any (i.e. one or more) of the four autoimmune diseases (a composite variable). To assess 
if there were effect modifications by sex and age-group, we conducted logistic regression 
analysis where we included in the model two-way interaction terms between each of the 
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autoimmune diseases and sex and between each of the autoimmune diseases and age-group, 
and three-way interaction terms between each of the autoimmune diseases, sex and age-
group, as well as the main effects variables for these factors and the other adjustment 
variables.
SAS version 9.3 (SAS Institute, Inc.) was used to conduct the analysis. Complex survey data 
analysis procedures (proc surveyfreq and proc surveylogistic) were used to adjust for the 
Nationwide Inpatient Sample sampling design, accounting for weights, strata, and clusters. 
The analysis was weighted to represent all non-maternal hospitalizations in the US among 
adults ≥19 years of age occurring in the types of hospitals included in the Health-care Cost 
and Utilization Project, Nationwide Inpatient Sample data base. Observations with missing 
information on the patient’s sex (0.1 %) and length of hospital stay (0.01 %) were excluded 
from regression analyses. Observations with missing race/ethnicity information (11 %) were 
classified into a ‘missing information’ response category for the race/ethnicity variable.
Results
In the study sample, there were 5,675,929 observations of hospitalizations among adults ≥19 
years of age that were not because of maternal causes (hereafter referred to simply as 
hospitalizations of both women and men) and of these, 136,120 hospitalizations had 
recorded diagnoses of one or more of the four autoimmune diseases of interest; 103,653 of 
these were among non-maternal hospitalizations of adult women (hereafter referred to 
simply as hospitalizations of women) and 32,445 were among hospitalizations of adult men 
(hereafter referred to simply as hospitalizations of men). The number of hospitalizations 
with a recorded diagnosis of AIHA, ITP, RA, and SLE were 2,866, 9,646, 94,585, and 
34,112, respectively, among hospitalizations of both women and men, 1,650, 5,305, 71,032, 
and 30,202, respectively, among hospitalizations of women, and 1,216, 4,336, 23,538, and 
3,908, respectively, among hospitalizations of men. There were 5,007 hospitalizations that 
had diagnoses of more than one of the four autoimmune diseases. The estimates presented 
here onwards in this paper are all weighted estimates. A diagnosis of VTE was recorded in 
2.28 % (95 % CI 2.22–2.34 %) of hospitalizations of both women and men that did not have 
a diagnosis of any of the four autoimmune diseases of interest (Fig. 1). In comparison, 
among hospitalizations of both women and men with recorded diagnoses of AIHA, ITP, RA, 
and SLE, a diagnosis of VTE was recorded in 4.46 % (95 % CI 3.70–5.22 %), 3.35 % (95 % 
CI 2.98–3.72 %), 2.65 % (95 % CI 2.77–2.89 %), and 2.77 % (95 % CI 2.57–2.97 %) of 
hospitalizations, respectively. Among hospitalizations of both women and men with 
recorded diagnoses of any of the autoimmune diseases of interest, a diagnosis of VTE was 
recorded in 2.84 % (95 % CI 2.72–2.96 %). The estimated percent of hospitalizations with a 
diagnosis of VTE are also presented separately for women and men in Fig. 1. Among 
hospitalizations of women without any of the autoimmune diseases of interest and among 
those with a diagnosis of SLE, the percent with a VTE diagnosis were 2.23 % (95 % CI 
2.18–2.28 %) and 2.45 % (95 % CI 2.65–2.85 %), respectively. The corresponding percents 
among hospitalizations of men were 2.33 % (95 % CI 2.27–2.39 %) and 3.64 % (95 % CI 
3.11–4.17 %), respectively.
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The unadjusted and adjusted ORs for recorded diagnosis of VTE among hospitalizations 
with recorded diagnoses of autoimmune diseases are presented in Table 1. The adjusted OR 
for recorded diagnoses of VTE was highest among hospitalizations of both women and men 
with recorded diagnoses of AIHA, followed by SLE, ITP, and RA (when compared to 
hospitalization of men and women without the respective autoimmune disease in each case). 
The adjusted OR for a diagnosis of VTE among hospitalizations of both women and men 
with any of the four autoimmune disorders was 1.20 (95 % CI 1.16–1.24) compared to 
hospitalizations of both women and men without the four autoimmune diseases. Of the two-
way interactions with sex, only those between sex and SLE and sex and ITP were 
statistically significant (p < 0.05); with regard to age-group, a two-way interaction was 
statistically significant (p < 0.05) only for SLE. A three-way interaction was statistically 
significant (p < 0.05) only for ITP. Table 2 presents ORs for VTE stratified by sex. The 
adjusted OR for VTE diagnosis among hospitalizations with a diagnosis of SLE (compared 
to hospitalizations without an SLE diagnosis) was higher among hospitalizations of men 
(OR 1.55, 95 % CI 1.33–1.80) than among hospitalizations of women (OR 1.19, 95 % CI 
1.11–1.28). When compared to hospitalizations not having a diagnosis of ITP, the adjusted 
OR for VTE associated with a diagnosis of ITP was higher among hospitalizations of 
women (OR 1.29, 95 % CI 1.10–1.51) than among hospitalizations of men, among whom 
the OR was not statistically significant (OR 1.10, 95 % CI 0.94–1.29).
Table 3 presents estimates of ORs for VTE stratified by age group. The adjusted ORs for 
VTE associated with a diagnosis of SLE (when compared to not having an SLE diagnosis) 
was higher among hospitalizations of both women and men who were 19–40 years of age 
(OR 1.82, 95 % CI 1.61–2.07) and 41–60 years of age (OR 1.14, 95 % CI 1.02–1.28) than 
those in the older age group, among which the OR did not reach statistical significance, (OR 
0.94, 95 % CI 0.84–1.05). Results of analysis stratified by sex and age-group are presented 
in Table 4. The highest OR for VTE associated with a diagnosis of ITP (when compared to 
not having a diagnosis of ITP) was among hospitalizations of women 19–40 years of age 
(OR 1.66, 95 % CI 1.12–2.45). Though the three-way interaction was not statistically 
significant for SLE, the highest OR for VTE associated with a diagnosis of SLE (compared 
to not having a diagnosis of SLE) was among hospitalizations of men 19–40 years of age 
(OR 2.79, 95 % CI 2.16–3.61).
Discussion
Our findings indicate that among non-maternal hospitalizations of adult patients in the 
United States, a recorded diagnosis of AIHA, ITP, RA, and SLE was significantly associated 
with an increased likelihood of having a recorded diagnosis of VTE. The percent of 
hospitalizations with a VTE diagnosis among those with a diagnosis of SLE was somewhat 
higher among hospitalizations of men compared to hospitalizations of women; the odds ratio 
for VTE diagnosis associated with an SLE diagnosis (compared to not having an SLE 
diagnosis) was also somewhat higher among hospitalizations of men than among 
hospitalizations of women. Age also appeared to be a significant effect modifier for the 
association with SLE where the OR for a VTE diagnosis associated with an SLE diagnosis 
(compared to not having an SLE diagnosis) was higher among hospitalizations of both 
women and men 19–40 years of age compared to hospitalizations of older women and men, 
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with the OR being less than one and not statistically significant for hospitalizations of those 
≥61 years of age. When stratified by both sex and age-group, the highest odds ratio for a 
VTE diagnosis associated with an ITP diagnosis (compared to not having an ITP diagnosis) 
was among hospitalizations of women 19–40 years of age. The findings of the current study 
add to the evidence suggesting that selected autoimmune diseases are associated with VTE 
occurrence.
There are several reasons why autoimmune disease may increase the risk of VTE. These 
reasons include that autoimmune diseases are commonly marked by inflammation, which 
increases the likelihood of thrombosis through several mechanisms including dysfunction of 
endothelium, increased tissue factor expression, increased levels of plasminogen activator 
inhibitor 1, and impairment of the protein C anticoagulant system [11, 16]. Also, higher 
levels of antiphospholipid antibodies (aPL) have been reported for SLE, RA, thyroid 
disease, and ITP, and other autoimmune diseases [11, 17]. Antiphospholipid antibodies may 
result in hypercoagulability and thrombosis by affecting the interaction between cell surface 
phospholipids and coagulation related proteins and possibly through other mechanisms as 
well [5, 11, 18, 19]. It is important to note there may be a higher risk of VTE regardless of 
the aPL status as other factors may influence thrombosis [5, 9, 11]. For example, it has been 
found that a substantial percent (~40 %) of SLE patients that suffer thrombosis do not have 
aPL [5]. It is also possible that an increased risk of VTE results, at least partially, from 
glucocorticoid therapy that may be associated with autoimmune diseases. A number of 
studies have indicated that glucocorticoids may increase the risk of VTE [20–24]. However, 
a review study reported that research findings showed that glucocorticoids had differential 
effects depending on the situation assessed [21]. Possible mechanisms of how 
glucocorticoids may increase VTE risk may include increased clotting factor and fibrinogen 
levels resulting from glucocorticoids [20, 21]. Another possible reason for the increased risk 
of VTE is that it is, at least in part, because of the increased risk of VTE that may be 
associated with chemotherapy, as chemotherapeutic agents may be used in the treatment of 
autoimmune diseases [25, 26]. More research is needed to better understand the reasons for 
the possible increased risk of VTE among patients with autoimmune diseases.
The increased OR for recorded diagnoses of VTE diagnosis among hospitalizations with 
diagnoses of the autoimmune diseases assessed in this study are consistent with a number of 
previous reports suggesting these disorders increase risk for developing VTE [5–10, 27, 28]. 
In a population-based cohort study conducted in Denmark that investigated the association 
between chronic ITP and VTE, it was found that the incidence risk ratio (IRR) for a primary 
diagnosis of VTE among patients with chronic ITP, compared to those in the reference 
group, was 2.65 (95 % CI 1.27–5.50); for provoked VTE (those with VTE related to cancer, 
fracture, trauma, surgery, or pregnancy/delivery) the IRR was 3.16 (95 % CI 1.11–8.98), and 
for unprovoked VTE, the IRR was 2.26 (95 % CI 0.81–6.30) [7]. Because of unavailable 
information, our study did not identify chronic ITP cases separately. A very serious possible 
complication of ITP is severe bleeding. Therefore, the possible increased risk of VTE among 
at least some ITP patients may cause additional difficulties in the clinical management of 
these patients; in addition, more investigation of this is needed.
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A study using US hospital discharge data reported that among hospitalizations without joint 
surgery, the relative risk for VTE among hospitalizations of patients with RA, compared to 
those without the disorder, was 1.99 (95 % CI 1.98–2.00) [6]. In addition, in a study 
conducted in China, the standard incidence ratio (SIR) for VTE among SLE patients in two 
hospitals (as compared to the general regional population) was found to be 11.9 (95 % CI 
7.3–19.6) [29]. In that study, the SIR was higher for SLE patients in younger age groups 
than for those in older age groups. The magnitude of the ORs associated with autoimmune 
diseases that have been reported by a number of other studies are substantially higher than 
found in our study [7, 9, 29]. Possible reasons for this may include differences in study 
designs and populations assessed. For instance, we used a cross-sectional approach to assess 
the risk of VTE diagnosis among hospitalizations with the four autoimmune diseases where 
the comparison group was all other no-maternal adult hospitalizations which themselves 
may have been at a higher risk of VTE diagnosis because hospitalized patients are more 
likely to have a VTE [1, 3] and because of other factors (e.g. other comorbidities that are 
risk factors for VTE). This could have resulted in the ORs found in our study being lower 
than they would have been if the comparison group was non-hospitalized persons.
Limitations of this study include that we used secondary data, and not data directly collected 
by the investigators through medical chart review. ICD-9-CM coded VTE diagnosis 
information recorded in discharge data are not always accurate. However, very good 
positive predictive values, 75–95 %, have been reported to be associated with many of the 
ICD-9-CM codes used to identify VTE diagnosis in this study [30]. The unit of study was 
the hospitalization and not the patient and it is likely some patients had more than one 
hospitalization in the study sample. Many of the VTE events among patients in this study 
may have occurred prior to hospitalization; however we did not have adequate information 
to identify all of these separately. Similarly, we were not able to assess VTE occurring after 
discharge from the hospital. Also, we did not have information regarding administration of 
VTE prophylaxis, which may have reduced the likelihood of VTE among hospitalized 
patients, and thus could not account for this. Similarly, we could not account for therapy, 
including glucocorticoids, or other treatment received by patients for autoimmune diseases 
that could have affected their disease condition and thus could have affected VTE 
occurrence. We also could not account for the status of autoimmune disease, e.g. acute state 
or under control. It was also possible that other factors could have affected or modified the 
associations between autoimmune diseases and VTE, but assessment for such was beyond 
the scope of the current study. Strengths of our study include that we were able to assess the 
association between VTE and the four autoimmune diseases in a large sample of 
hospitalizations from across the US. We were also able to control for selected demographic 
characteristics and comorbidities during the analysis.
The autoimmune diseases, AIHA, ITP, RA, and SLE may be associated with an increased 
risk of VTE among hospitalized patients. The risk of VTE among patients with SLE may 
vary by sex and by age-group. Current VTE prevention guidelines of the American College 
of Chest Physicians indicate antiphospholipid syndrome as a risk factor for VTE when 
assessing risk level among hospitalized medical patients. Such guidelines can help in clinical 
decision making regarding patients for consideration for VTE prophylaxis [31]. Also, 
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additional research can help develop a more comprehensive understanding of the effect of 
autoimmune diseases on VTE risk among hospitalized patients.
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Appendix
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
codes used
Diagnosis codes used:
DVT 451.1, 451.11, 451.19, 451.81, 451.83, 451.89, 453.2, 453.4, 453.40, 453.41, 
453.42, 453.82, 453.84, 453.85;
PE 415.1, 415.11, 415.19.;
Autoimmune hemolytic anemia 283.0;
Immune thrombocytopenic purpura 287.31;
Rheumatoid arthritis 714, 714.0;
Systemic lupus erythematosus 710.0;
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Heart failure 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 
428.xx;
Stroke 431, 434.xx, 436;
Infection 001.xx–139.xx, 460.xx-466.xx, 480.xx-488.xx;
Long bone fracture 812.xx, 813.xx, 820.xx, 821.xx, 823.xx.
Procedure code used:
Venous catheterization 38.93.
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Rate of hospitalizations with a recorded diagnosis of venous thromboembolism among 
hospitalizations with and without autoimmune diseases. No AID no autoimmune disease, 
AIHA autoimmune hemolytic anemia, ITP immune thrombocytopenic purpura, RA 
rheumatoid arthritis, SLE systemic lupus erythematosus, 1+ AID one or more of the four 
autoimmune diseases. Hairlines indicate 95 % confidence limits of the respective estimates
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Table 1
Unadjusted and adjusted odds ratios for recorded diagnoses of venous thromboembolism among adult non-
maternal hospitalizations with selected autoimmune diseases, Nationwide Inpatient Sample, 2010
Characteristic Unweighted sample size Unadjusted OR (95 % CI) for VTE Adjusted OR (95 % CI) for VTE
Autoimmune hemolytic anemia 2,866 2.00 (1.68–2.38) 1.25 (1.05–1.49)
Immune thrombocytopenic purpura 9,646 1.49 (1.33–1.66) 1.20 (1.07–1.34)
Rheumatoid arthritis 94,585 1.22 (1.17–1.27) 1.17 (1.13–1.21)
Systemic lupus erythematosus 34,112 1.22 (1.13–1.31) 1.23 (1.15–1.32)
One or more of the above diseases 136,120 1.25 (1.21–1.30) 1.20 (1.16–1.24)
The analysis was weighted to represent all non-maternal hospitalizations among adults ≥19 years age in non-rehabilitation community hospitals
The reference group for the odds ratios is all hospitalizations without the respective autoimmune disease
In adjusted analysis, the factors adjusted for are sex, race/ethnicity, age, selected medical risk factors (cancer, congestive heart failure, stroke, long 
bone fracture, and infection), venous catheterization, major surgery, and length of hospital stay. Since all four autoimmune diseases were included 
in a model, the results for each are adjusted with respect to the other three
OR odds ratio, CI confidence interval, VTE venous thromboembolism
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Table 2
Unadjusted and adjusted odds ratios for recorded diagnoses of venous thromboembolism among adult non-
maternal hospitalizations with selected autoimmune diseases, by sex, Nationwide Inpatient Sample, 2010
Characteristic Women OR (95 % CI) for VTE Men OR (95 % CI) for VTE
Unadjusted odds ratios
 Autoimmune hemolytic anemia 2.13 (1.70–2.66) 1.84 (1.42–2.38)
 Immune thrombocytopenic purpura 1.59 (1.36–1.86) 1.36 (1.16–1.60)
 Rheumatoid arthritis 1.23 (1.18–1.29) 1.24 (1.15–1.34)
 Systemic lupus erythematosus 1.19 (1.11–1.28) 1.57 (1.36–1.83)
 One or more of the above diseases 1.25 (1.21–1.30) 1.32 (1.23–1.41)
Adjusted odds ratios
 Autoimmune hemolytic anemia 1.36 (1.08–1.71) 1.14 (0.88–1.48)
 Immune thrombocytopenic purpura 1.29 (1.10–1.51) 1.10 (0.94–1.29)
 Rheumatoid arthritis 1.16 (1.11–1.21) 1.17 (1.08–1.26)
 Systemic lupus erythematosus 1.19 (1.11–1.28) 1.55 (1.33–1.80)
 One or more of the above diseases 1.20 (1.15–1.24) 1.21 (1.14–1.29)
The analysis was weighted to represent all non-maternal hospitalizations among adults ≥19 years age in non-rehabilitation community hospitals
The reference group for the odds ratios is all hospitalizations without the respective autoimmune disease
In adjusted analysis, the factors adjusted for are race/ethnicity, age, selected medical risk factors (cancer, congestive heart failure, stroke, long bone 
fracture, and infection), venous catheterization, major surgery, and length of hospital stay. Since all four autoimmune diseases were included in a 
model, the results for each are adjusted with respect to the other three
OR odds ratio, CI confidence interval, VTE venous thromboembolism
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Table 3
Unadjusted and adjusted odds ratios for recorded diagnoses of venous thromboembolism among adult non-
maternal hospitalizations with selected autoimmune diseases, by age-group, Nationwide Inpatient Sample, 
2010
Characteristic
19–40 Years of age OR (95 % 
CI)
41–60 Years of age OR (95 % 
CI)
≥61 Years of age OR (95 % 
CI)
Unadjusted odds ratios
 Autoimmune hemolytic anemia 2.03 (1.16–3.57) 2.62 (1.91–3.58) 1.76 (1.42–2.18)
 Immune thrombocytopenic purpura 1.72 (1.23–2.41) 1.49 (1.19–1.86) 1.43 (1.25–1.64)
 Rheumatoid arthritis 1.47 (1.22–1.78) 1.12 (1.02–1.21) 1.16 (1.11–1.21)
 Systemic lupus erythematosus 2.28 (2.02–2.57) 1.15 (1.02–1.29) 1.00 (0.90–1.11)
 Overall (one or more of above) 1.95 (1.75–2.17) 1.17 (1.08–1.26) 1.17 (1.13–1.22)
Adjusted odds ratios
 Autoimmune hemolytic anemia 1.14 (0.64–2.03) 1.53 (1.10–2.13) 1.19 (0.96–1.48)
 Immune thrombocytopenic purpura 1.40 (1.01–1.95) 1.22 (0.97–1.53) 1.17 (1.02–1.35)
 Rheumatoid arthritis 1.20 (0.99–1.45) 1.17 (1.08–1.28) 1.16 (1.11–1.21)
 Systemic lupus erythematosus 1.82 (1.61–2.07) 1.14 (1.02–1.28) 0.94 (0.84–1.05)
 Overall (one or more of above) 1.67 (1.48–1.85) 1.19 (1.10–1.28) 1.14 (1.10–1.18)
The analysis was weighted to represent all non-maternal hospitalizations among adults ≥19 years age in non-rehabilitation community hospitals
The reference group for the odds ratios is all hospitalizations without the respective autoimmune disease
In adjusted analysis, the factors adjusted for are sex, race/ethnicity, selected medical risk factors (cancer, congestive heart failure, stroke, long bone 
fracture, and infection), venous catheterization, major surgery, and length of hospital stay. Since all four autoimmune diseases were included in a 
model, the results for each are adjusted with respect to the other three
OR odds ratio, CI confidence interval
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Table 4
Adjusted odds ratios for recorded diagnoses of venous thromboembolism among adult non-maternal 
hospitalizations with selected autoimmune diseases, by sex and age-group, Nationwide Inpatient Sample, 2010
Characteristic
19–40 Years of age OR (95 % 
CI)
41–60 Years of age OR (95 % 
CI)
≥61 years of age OR (95 % 
CI)
Among women
 Autoimmune hemolytic anemia 1.14 (0.58–2.23) 1.67 (1.07–2.61) 1.30 (0.97–1.75)
 Immune thrombocytopenic purpura 1.66 (1.12–2.45) 1.48 (1.11–1.97) 1.14 (0.94–1.38)
 Rheumatoid arthritis 1.15 (0.92–1.45) 1.21 (1.10–1.33) 1.15 (1.09–1.21)
 Systemic lupus erythematosus 1.68 (1.47–1.93) 1.10 (0.98–1.24) 0.92 (0.82–1.03)
 One or more of the above 1.58 (1.40–1.78) 1.21 (1.11–1.31) 1.13 (1.08–1.18)
Among men
 Autoimmune hemolytic anemia 1.23 (0.50–3.04) 1.40 (0.85–2.30) 1.06 (0.77–1.46)
 Immune thrombocytopenic purpura 0.94 (0.54–1.62) 0.91 (0.63–1.30) 1.21 (0.99–1.48)
 Rheumatoid arthritis 1.47 (0.96–2.24) 1.12 (0.95–1.31) 1.18 (1.09–1.29)
 Systemic lupus erythematosus 2.79 (2.16–3.61) 1.31 (1.02–1.69) 1.07 (0.81–1.42)
 One or more of the above 1.98 (1.59–2.46) 1.14 (1.00–1.31) 1.18 (1.10–1.27)
The analysis was weighted to represent all non-maternal hospitalizations among adults ≥19 years age in non-rehabilitation community hospitals
The reference group for the odds ratios is all hospitalizations without the respective autoimmune disease
In adjusted analysis, the factors adjusted for are race/ethnicity, selected medical risk factors (cancer, congestive heart failure, stroke, long bone 
fracture, and infection), immune thrombocytopenic purpura, rheumatoid arthritis, venous catheterization, major surgery, and length of hospital stay. 
Since all four autoimmune diseases were included in a model, the results for each are adjusted with respect to the other three
OR odds ratio, CI confidence interval
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